Cannabis and cannabis extracts: Greater than the sum of their parts?

The Handbook of Cannabis Therapeutics: From Bench to Bedside

Volumn , Issue , 2014, Pages 171-204

  McPartland, John M ^a   Russo, Ethan B ^b  

^a Porton Down Science Park   (United Kingdom)

^b UNIVERSITY OF MONTANA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84872103139     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1300/5741_10     Document Type: Chapter

References (184)

1. Abrahamov, A., and R. Mechoulam. 1995. An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci 56(23-24):2097-2102.
2. Achiron, A., S. Miron, V. Lavie, R. Margalit, and A. Biegon. 2000. Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: Implications for the treatment of acute relapses of multiple sclerosis. JNeuroimmunol 102(1): 26-31.
3. Agrawal, A.K., P. Kumar, A. Gulati, and P.K. Seth. 1989. Cannabis-induced neuro-toxicity in mice: Effects on cholinergic (muscarinic) receptors and blood brain barrier permeability. Res Commun Subst Abuse 10:155-168.
4. Anderson, P.F., D.M. Jackson, and G.B. Chesher. 1974. Interaction of delta-9-tetrahydrocannabinol and cannabidiol on intestinal motility in mice. J Pharm Pharmacol 26(2):136-137.
5. Aydin, S., T. Demir, Y. Ozturk, and K.H. Baser. 1999. Analgesic activity of Nepeta italica L. Phytother Res 13(1):20-23.
6. Baek, S.H., Y.O. Kim, J.S. Kwag, K.E. Choi, W.Y. Jung, and D.S. Han. 1998. Boron trifluoride etherate on silica-A modified Lewis acid reagent (VII). Antitumor activity of cannabigerol against human oral epitheloid carcinoma cells. Arch Pharmacol Res 21:353-356.
7. Banerjee, S.P., S.H. Snyder, and R. Mechoulam. 1975. Cannabinoids: Influence on neurotransmitter uptake in rat brain synaptosomes. J Pharmacol Exper Therap 194:74-81.
8. Barrett, M.L., A.M. Scutt, and F.J. Evans. 1986. Cannflavin A and B, prenylated fla-vones from Cannabis sativa L. Experientia 42:452-453.
9. Basile, A.C., J.A. Sertie, P.C. Freitas, and A.C. Zanini. 1988. Anti-inflammatory activity of oleoresin from Brazilian Copaifera. J Ethnopharmacol 22(1):101-109.
10. Biegon, A., and A.B. Joseph. 1995. Development of HU-211 as a neuroprotectant for ischemic brain damage. Neurol Res 17(4):275-280.
11. Bisset, N.G. and M. Wichtl. 1994. Herbal drugs and phytopharmaceuticals: A handbook for practice on a scientific basis. Stuttgart, Boca Raton: Medpharm Scientific Publishers, CRC Press.
12. Bornheim, L.M., K.Y. Kim, J. Li, B.Y. Perotti, and L.Z. Benet. 1995. Effect of cannabidiol pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain. Drug Metab Dispos 23:825-831.
13. Boucher, F., M. Paris, and L. Cosson. 1977. Mise en évidence de deux type chimques chez le Cannabis sativa originaire d'Afrique du Sud. Phytochem 16:1445-1448.
14. British Medical Association. 1997. Therapeutic uses of cannabis. Amsterdam: Harwood Academic Publishers.
15. Brodkin, J., and J.M. Moerschbaecher. 1997. SR141716A antagonizes the disruptive effects of cannabinoid ligaands on learning in rats. J Pharmacol Exper Therap282:1526-1532.
16. Browne, R.G., and A. Weissman. 1981. Discriminative stimulus properties of delta 9-tetrahydrocannabinol: Mechanistic studies. J Clin Pharmacol 21(8-9 Suppl): 227S-234S.
17. Buchbauer, G., L. Jirovetz, W. Jager, C. Plank, and H. Dietrich. 1993. Fragrance compounds and essential oils with sedative effects upon inhalation. J Pharm Sci 82(6):660-664.
18. Buckingham, J. (ed.) 1992. Dictionary of natural products. London: Chapman & Hall.
19. Burits, M., and F. Bucar. 2000. Antioxidant activity of Nigella sativa essential oil. Phytoth Res 14(5):323-328.
20. 9-tetrahydrocannabinol. Proc Soc Exp Biol Med 210:64-76.
21. Burstein, S., E. Levin, and C. Varanelli. 1973. Prostaglandins and Cannabis-II. Inhibition of biosynthesis by the naturally occurring cannabinoids. Biochem Pharmacol 22:2905-2910.
22. Burstein, S., P. Taylor, F.S. El-Feraly, C. Turner. 1976. Prostaglandins and Cannabis-V. Identification of p-vinylphenol as a potent inhibitor of prostaglandin synthesis. Biochem Pharmacol 25:2003-2004.
23. Burstein, S., C. Varanelli, and L.T. Slade. 1975. Prostaglandins and Cannabis-III. Inhibition of biosynthesis by essential oil components of marihuana. Biochemical Pharmacology 24:1053-1054.
24. Campbell, W.E., D.W. Gammon, P. Smith, M. Abrahams, and T.D. Purves. 1997. Composition and antimalarial activity in vitro of the essential oil of Tetradenia riparia. Planta Med 63(3):270-272.
25. Carlini, E.A., and J.M. Cunha. 1981. Hypnotic and antiepileptic effects of cannabidiol. J Clin Pharmacol 21:417S-427S.
26. Carlini, E.A., I. G. Karniol, P.F. Renault, and C.R. Schuster. 1974. Effects of marihuana in laboratory animals and man. Brit J Pharmacol 50:299-309.
27. Carson, C.F., and T.V. Riley. 1995. Antimicrobial activity of the major components of the essential oil of Melaleuca alternifolia. J Appl Bacter 78(3):264-269.
28. 9-tetrahydrocannabinol in rats. Brain Res 809:1-4.
29. Cheney, D.L., A.V. Revuelta, and E. Costa. 1981. Marijuana and cholinergic dynamics. In G. Pepeu and H. Ladinsky (eds.), Cholinergic mechanisms: Phylogenetic aspects, central and peripheral synapses, and clinical significance (pp. 825-832). New York: Plenum Press.
30. Clarke, R.C. 1998. Hashish! Los Angeles, CA: Red Eye Press.
31. Compton, D.R., K.C. Rice, B.R. DeCosta, R.K. Razdan, L.S. Melvin, M.R. Johnson, and B.R. Martin. 1993. Cannabinoid structure-activity relationships: Correlation of receptor binding and in vivo activities. J Pharmacol Exp Therap 265:218-226.
32. Consroe, P. 1998. Brain cannabinoid systems as targets for the therapy of neurological disorders. Neurobiol Dis 5:534-551.
33. Costa, T.R., O.F. Fernandes, S.C. Santos, C.M. Oliveira, L.M. Liao, P.H. Ferri, J.R. Paula, H.D. Ferreira, B.H. Sales, and M.R. Silva. 2000. Antifungal activity of volatile constituents of Eugenia dysenterica leaf oil. J Ethnopharmacol 72(1-2): 111-117.
34. Crowell, P.L. 1999. Prevention and therapy of cancer by dietary monoterpenes. J Nutr 129:775S-778S.
35. 9-tetrahydrocannabinol is mediated by nuclear factor κB and CB1 cannabinoid receptor. DNA Cell Biol 16:301-309.
36. Dalterio, S., D. Mayfield, A. Bartke, W. Morgan. 1985. Effects of psychoactive and non-psychoactive cannabinoids on neuroendocrine and testicular responsiveness in mice. Life Sci 36:1299-1306.
37. 9-tetrahydrocannabinol. Gen Pharmacol 14(2): 247-252.
38. De Oliveira, A.C., L.F. Ribeiro-Pinto, J.R. Paumgartten. 1997. In vitro inhibition of CYP2B1 monooxygenase by beta-myrcene and other monoterpenoid compounds. Toxicol Lett 92:39-46.
39. Devane, W.A., F.A. Dysarz, M.R. Johnson, L.S. Melvin, A.C. Howlett. 1988. Determination and characterization of a cannabinoid receptor in rat brain. Molecular Pharmacol 34:605-613.
40. Di Marzo, V. and A. Fontana. 1995. Anandamide, an endogenous cannabinomimetic eicosanoid: "Killing two birds with one stone." Prostagland Leukotr Essent Fatty Acids 53:1-11.
41. 9-terahydrocannabinol and cannabinol on rat brain acetylcholine. In Nahas G.G., Panton W.D.M., Idanpaan-Heikkila J.E. (eds.), Marijuana: chemistry, biochemistry, and cellular effects (pp. 407-413). New York: Springer-Verlag.
42. ElSohly, M.A., S. Feng, T.P. Murphy, S.A. Ross, A. Nimrod, Z. Mehmedic, and N. Fortner. 1999. Delta-9-tetrahydrocannabivarin (delta-9-THCV) as a marker for the ingestion of cannabis versus Marinol. J Analyt Toxicol 23(3):222-224.
43. ElSohly, H.N., C.E. Turner, A.M. Clark, and M.A. ElSohly. 1982. Synthesis and antimicrobial activities of certain cannabichromene and cannabigerol related compounds. J Pharmaceut Sci 71:1319-1323.
44. Evans, A.T., E.A. Formukong, and F.J. Evans. 1987. Actions of cannabis constituents on enzymes of arachidonate metabolism: Anti-inflammatory potential. Bioch Pharmacol 36:2035-2037.
45. Evans, F.J. 1991. Cannabinoids: the separation of central from peripheral effects on a structural basis. Planta Med 57(Suppl 1):S60-S67.
46. 1-trans-tetrahydro-cannabinol content. British J Pharmacol 72:401-409.
47. Falk, A.A., M.T. Hagberg, A.E. Lof, E.M. Wigaeus-Hjelm, and Z.P. Wang. 1990. Uptake, distribution and elimination of alpha-pinene in man after exposure by inhalation. Scand J Work Envir Health 16(5):372-378.
48. Falk-Filipsson, A., A. Löf, M. Hagberg, E.W. Hjelm, and Z. Wang. 1993. d-Limonene exposure to humans by inhalation: Uptake, distribution, elimination, and effects on the pulmonary function. J Toxicol Envir Health 38:77-88.
49. Faubert, B.L., and N.E. Kaminski. 2000. AP-1 activity is negatively regulated by cannabinol through inhibition of its protein components, c-fos and c-jun. J Leukocyte Biol 67:259-266.
50. Fenselau, C., and G. Hermann. 1972. Identification of phytosterols in red oil extract of cannabis. J Forens Sci 17(2):309-312.
51. Foletta, V.C., D.H. Segal, and D.R. Cohen. 1998. Transcriptional regulation in the immune system: all roads lead to AP-1. J Leukocyte Biol 63:139-152.
52. Formukong, E.A., A.T. Evans, and F.J. Evans. 1988. Inhibition of the cataleptic effect of tetrahydrocannabinol by other constituents of Cannabis sativa L. J Pharm Pharmacol 40:132-134.
53. Fournier, G., C. Richez-Dumanois, J. Duvezin, J.P. Mathieu, and M. Paris. 1987. Identification of a new chemotype in Cannabis sativa: Cannabigerol-dominant plants, biogenetic and agronomic prospects. Planta Med 53:277-280.
54. Franchomme, P., and Pénoël. 1990. L'aromathérapie exactement. Limoges, France: Roger Jallois.
55. Fuhr, U. 1998. Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance. Drug Safety 18:251-272.
56. Gadow, A von, E. Joubert, and C.G. Hansmann. 1997. Comparison of the antioxidant activity of aspalathin with that of other plant phenols of rooibos tea (Aspalathus linearis), α-tocopherol, BHT, and BHA. J Agricult Food Chem 45: 632-638.
57. Gallily, R., A. Yamin, Y. Waksmann, H. Ovadia, J. Weidenfeld, A. Bar-Joseph, A. Biegon, R. Mechoulam, and E. Shohami. 1997. Protection against septic shock and suppression of tumor necrosis factor alpha and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid. J Pharm Exper Therap 283(2):918-924.
58. Gerritsen, M.E., W.W. Carley, G.E. Ranges, C.-P. Shen, S.A. Phan, G.F. Ligon, and C.A. Perry. 1995. Flavonoids inhibit cytokine-induced endothelial cell adhesion protein gene expression. Am J Path 147:278-292.
59. Gieringer, D. 1996. Marijuana research: Waterpipe study. MAPS [Multidisciplinary Association for Psychedelic Studies] Bull 6(3):59-66.
60. Gieringer, D. 2001. NORML study shows vaporizers reduce marijuana smoke toxins. California NORML Reports 25(1):2.
61. Gil, M.L., J. Jimenez, M.A. Ocete, A. Zarzuelo, and M.M. Cabo. 1989. Comparative study of different essential oils of Bupleurum gibraltaricum Lamarck. Pharmazie 44(4):284-287.
62. Gill, E.W., W.D.M. Paton, and R.G. Pertwee. 1970. Preliminary experiments on the chemistry and pharmacology of Cannabis. Nature 228:134-136.
63. Gomez, M.A., M.T. Saenz, M.D. Garcia, and M.A. Fernandez. 1999. Study of the topical anti-inflammatory activity of Achillea ageratum on chronic and acute inflammation models. Zeitscrift fur Naturforsch [C] 54 (11):937-941.
64. Greene-McDowelle, D.M., B. Ingber, M.S. Wright, H.J. Zeringue, D. Bhatnagar, and T.E. Cleveland. 1999. The effects of selected cotton-leaf volatiles on growth, development and aflatoxin production of Aspergillus parasiticus. Toxicon 37:883-893.
65. Greenspan, H.C. 1993. The role of reactive oxygen species, antioxidants and phytopharmaceuticals in human immunodeficiency virus activity. Med Hypoth 40:85-92.
66. Grinspoon, L., J.B. Bakalar. 1997. Marihuana, the forbidden medicine, Revised edition. New Haven, CT: Yale University Press.
67. Guenther, E. 1948. The essential oils: Individual essential oils of the plant families. New York: D. Van Nostrand.
68. Gwanzura, L., W. McFarland, D. Alexander, R. L. Burke, and D. Katzenstein. 1998. Association between human immunodeficiency virus and herpes simplex virus type 2 seropositivity among male factory workers in Zimbabwe. J Infect Dis 177(2):481-484.
69. Hammerschmidt, F.J., A.M. Clark, F.M. Soliman, E.S. el-Kashoury, M.M. Abd el-Kawy, and A.M. el-Fishawy. 1993. Chemical composition and antimicrobial activity of essential oils of Jasonia candicans and J. montana. Planta Med 59(1):68-70.
70. 9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci 95:8268-8273.
71. Hardcastle, I.R., M.G. Rowlands, A.M. Barber, R.M. Grimshaw, M.K. Mohan, B.P. Nutley, and M. Jarman. 1999. Inhibition of protein prenylation by metabolites of limonene. Biochem Pharmacol 57:801-809.
72. 9-tetrahydrocannabinol: Interactions relative to lethality, hypothermia, and hexobarbital hypnosis. Gen Pharmacol 12:357-362.
73. Herring, A.C., N.E. Kaminski. 1999. Cannabinol-mediated inhibition of nuclear factor-κB, cAMP response element-binding protein, and interleukin-2 secretion by activated thymocytes. J Pharmacol Exp Therap 291:1156-1163.
74. 9-tetrahydro-cannabinol on delayed match to sample performance in rats: Alterations in shortterm memory associated with changes in task specific firing of hippocampal cells. J Pharmacol Exp Therap264:294-307.
75. Hollister, L.E. 1974. Structure-activity relationships in man of cannabis constituents, and homologs and metabolites of delta-9-tetrahydrocannabinol. Pharmacol 11(1):3-11.
76. Hudson, B.J.F., and S.E.O. Mahgoub. 1981. Synergism between phospholipids and naturally-occurring antioxidants in leaf lipids. J Sci Food Agricult 32:208-210.
77. Iversen, L.L. 2000. The science of marijuana. Oxford, UK: Oxford University Press.
78. Jones, C.L.A. 1999. Monoterpenes: Essence of a cancer cure. Nutr Sci News 4 (4):190.
79. Kapeghian, J.C., A.B. Jones, J.C. Murphy, M.A. Elsohly, and C.E. Turner. 1983. Effect of cannabichromene on hepatic microsomal enzyme activity in the mouse. Gen Pharmacol 14:361-363.
80. Klein, T.W., H. Friedman, and S. Specter. 1998. Marijuana, immunity and infection. J Neuroimmunol 83:102-105.
81. Klein, T.W., C. Newton, and H. Friedman. 1987. Inhibition of natural killer cell function by marijuana components. J Toxicol Envir Health 20:321-332.
82. 9-tetrahydro-cannabinol and cannabidiol. Antonie van Leeuwenhoek 42:9-12.
83. Komori, T., R. Fujiwara, M. Tanida, J. Nomura, and M.M. Yokoyama. 1995. Effects of citrus fragrance on immune function and depressive states. Neuroimmunomod 2:174-180.
84. Kovar, K.A., B. Gropper, D. Friess, and H.P. Ammon. 1987. Blood levels of 1, 8-cineole and locomotor activity of mice after inhalation and oral administration of rosemary oil. Planta Med 53(4):315-318.
85. Kubena, R.K., and H. Barry. 1972. Stimulus characteristics of marihuana components. Nature 235:397-398.
86. Lawless, J. 1995. The illustrated encyclopedia of essential oils: The complete guide to the use of oils in aromatherapy and herbalism. Shaftesbury, Dorset, UK: Element.
87. Liu, S.L. 1990. [Therapeutic effects of borneol-walnut oil in the treatment of purulent otitis media]. Chung Hsi I Chieh Ho Tsa Chih 10(2):93-95, 69.
88. Lorenzetti, B.B., G.E.P. Souza, S.J. Sarti, D. Santos Filho, and S.H. Ferreira. 1991. Myrcene mimics the peripheral analgesic activity of lemongrass tea. J Ethnopharmacol 34:43-48.
89. Malfait, A.M., R. Gallily, P.F. Sumariwalla, A.S. Malik, E. Andreakos, R. Mechoulam, and M. Feldman. 2000. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci 97:9561-9566.
90. Malingré, T., H. Hendriks, S. Batterman, R. Bos, and J. Visser. 1973. The essential oil of Cannabis sativa. Planta Med 28:56-61.
91. Marcihac, A., N. Dakine, N. Bourhim, V. Guillaume, M. Grino, K. Drieu, and C. Oliver. 1998. Effect of chronic administration of Ginkgo biloba extract or kinkgolide on the hypothalamic-pituitary-adrenal axis in the rat. Life Sci 62:2329-2340.
92. Martin, L., D.M. Smith, and C.G. Farmilo. 1961. Essential oil from fresh Cannabis sativa and its use in identification. Nature 191:774-776.
93. Mathew, R.J., and W.H. Wilson. 1993. Acute changes in cerebral blood flow after smoking marijuana. Life Sci 52:757-767.
94. McPartland, J.M. 1984. Pathogenicity of Phomopsis ganjae on Cannabis sativa and the fungistatic effect of cannabinoids produced by the host. Mycopathologia 87: 149-153.
95. McPartland, J.M. 1996. Viral hepatitis treated with Phyllanthus amarus and milk thistle (Silybum marianum): A case report. Complement Med Internat 3(2):40-42.
96. McPartland, J.M. 1997. Cannabis as a repellent crop and botanical pesticide. J Internat Hemp Assoc 4(2):89-94.
97. McPartland, J.M., R.C. Clarke, and D.P. Watson. 2000. Hemp diseases and pests: Management and biological control. Wallingford: UK. CABI.
98. McPartland, J.M., and P.P. Pruitt. 1997. Medical marijuana and its use by the immunocompromised. Altern Therap 3(3):39-45.
99. McPartland, J.M., and P.P. Pruitt. 1999. Side effects of pharmaceuticals not elicited by comparable herbal medicines: The case of tetrahydrocannabinol and marijuana. Altern Therap 5(4):57-62.
100. McPartland, J.M., and P.L. Pruitt. 2000. Benign prostatic hyperplasia treated with saw palmetto: A literature search and an experimental case study. J Amer Osteopath Assoc 100(2):89-96.
101. Mechoulam, R., and S. Ben-Shabat. 1999. From gan-zi-gun-nu to anandamide and 2-arachidonoylglycerol: The ongoing story of cannabis. Nat Prod Rep16(2):131-143.
102. Mechoulam, R., Z. Ben-Zvi, A. Shani, H. Zemler, and S. Levy. 1972. Cannabinoids and Cannabis activity. In W.D.M Paton and J. Crown (eds.), Cannabis and its derivatives (pp. 1-13). London: Oxford University Press.
103. Mechoulam, R., and Y. Gaoni. 1965. Hashish-IV. The isolation and structure of cannabinolic, cannabidiolic, and cannabigerolic acids. Tetrahedr 21:1223-1229.
104. Mechoulam, R., and Y. Gaoni. 1967. Recent advances in the chemistry of hashish. Fortschritte der Chemie Organischer Naturstoffe 25:175-213.
105. Mediavilla, V., and S. Steinemann. 1997. Essential oil of Cannabis sativa L. strains. J Internat Hemp Assoc 4(2):82-84.
106. Meier, C., Mediavilla, V. 1998. Factors influencing the yield and the quality of hemp (Cannabis sativa L.) essential oil. J Internat Hemp Assoc 5(1):16-20.
107. Merkus, F.W.H.M. 1971. Cannabivarin and tetrahydrocannabivarin, two new constituents of hashish. Nature 232:580-581.
108. Meschler, J.P., and A.C. Howlett. 1999. Thujone exhibits low affinity for canna-binoid receptors but fails to evoke cannabimimetic responses. Pharmacol Biochem Behav 62:473-480.
109. Misner, D.L., and J.M. Sullivan. 1999. Mechanism of cannabinoid effects on longterm potentiation and depression in hippocampal CA1 neurons. J Neurosci 19(16): 6795-6805.
110. Miyazawa, M., H. Watanabe, and H. Kameoka. 1997. Inhibition of acetylcholinesterase activity by monoterpenoids with a p-methane skeleton. J Agricult Food Chem 45:677-679.
111. Musonda, C.A., and J.K. Chipman. 1998. Quercetin inhibits hydrogen peroxide-induced NF-κB DNA binding activity and DNA damage in HepG2 cells. Carcinogen 19:1583-1589.
112. 9-THC and cannabinol in man. In: Pharmacology of marihuana, MC Braude and S. Szara, eds. Raven Press, NY. Vol. 2:559-563.
113. Nasel, C., B. Nasel, P. Samec, E. Schindler, and G. Buchbauer. 1994. Functional imaging of effects of fragrances on the human brain after prolonged inhalation. Chem Senses 19:359-364.
114. Nigam, M.C., K.L. Handa, I.C. Nigam, and L. Levi. 1965. Essential oils and their constituents. XXIX. The essential oil of marihuana: composition of the genuine Indian Cannabis sativa L. Canad J Chem 43:3372-3376.
115. Offord, E.A., K. Macé, O. Avanti, and A.M.A. Pfeifer. 1997. Mechanisms involved in the chemoprotective effects of rosemary extract studied in human liver and bronchial cells. Cancer Lett 114:275-281.
116. Ohlsson, A., J.E. Lindgren, A. Wahlen, S. Agurell, L.E. Hollister, and H.K. Gillespie. 1980. Plasma Δ9-tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Therap28:409-416.
117. Onawunmi, G.O., W.A. Yisak, and E.O. Ogunlana. 1984. Antibacterial constituents in the essential oil of Cymbopogon citratus (DC.) Stapf. J Ethnopharmacol 12(3): 279-286.
118. O'Neil, J.D., W.S. Dalton, and R.B. Forney. 1979. The effect of cannabi-chromene on mean blood pressure, heart rate, and respiration rate responses to tetrahydrocannabinol in the anesthetized rat. Toxicol Appl Pharmacol 49:265-270.
119. Ortiz de Urbina, A.V., M.L. Martin, M.J. Montero, A. Moran, and L. San Roman. 1989. Sedating and antipyretic activity of the essential oil of Calamintha sylvatica subsp. ascendens. J Ethnopharmacol 25(2):165-171.
120. Paris, R.R., E. Henri, and M. Paris. 1976. Sur les c-flavonoïdes du Cannabis sativa L. Plantes Médicinales et Phytothérapie 10:144-154.
121. Parry, E.J. 1918. The chemistry of essential oils and artificial perfumes. 2 vols. London: Scott, Greenwood and Son.
122. Pate, D. 1994. Chemical ecology of cannabis. J Internat Hemp Assoc 2:32-37.
123. Pate, D. 1999. Anandamide structure-activity relationships and mechanisms of action on intraocular pressure in the normotensive rabbit model. Doctoral thesis, University of Kuopio, Finland, 99 pp.
124. Perry, N., G. Court, N. Bidet, J. Court, and E. Perry. 1996. European herbs with cholinergic activity: Potential in dementia therapy. Internat J Geriatr Psych 11: 1063-1069.
125. Perry, N.S., P.J. Houghton, A. Theobald, P. Jenner, and E.K. Perry. 2000. In-vitro inhibition of human erythrocyte acetylcholinesterase by salvia lavandulaefolia essential oil and constituent terpenes. J Pharm Pharmacol 52(7):895-902.
126. 9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci 63:PL1-PL6.
127. Pitts, J.E., J.D. Neal, and T.A. Gough. 1992. Some features of Cannabis plants grown in the United Kingdom from seeds of known origin. J Pharm Pharmacol 44(12): 947-951.
128. Poddar, M.K., and W.L. Dewey. 1980. Effects of cannabinoids on catecholamine uptake and release in hypothalamic and striatal synaptosomes. J Pharmacol Exper Therap214:63-67.
129. Poirier, J., M.C. Delisle, R. Quirion, I. Aubert, M. Farlow, D. Lahiri, S. Hui, P. Bertrand, J. Nalbantoglu, B.M. Gilfix, and S. Gauthier. 1995. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer's disease. Proc Natl Acad Sci 92:12260-12264.
130. Raman, A., U. Weir, and S.F. Bloomfield. 1995. Antimicrobial effects of tea-tree oil and its major components on Staphylococcus aureus, Staph. epidermidis and Propionibacterium acnes. Lett Appl Microbiol 21(4):242-245.
131. Rao, V.S.N., A.M.S. Menezes, and G.S.B. Viana. 1990. Effect of myrcene on nociception in mice. J Pharm Pharmacol 42:877-878.
132. 37) CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats. J Pharm ExpTherap276:56-64.
133. Rose, J.E., and F.M. Behm. 1994. Inhalation of vapor from black pepper extract reduces smoking withdrawal symptoms. Drug Alcohol Dep 34(3):225-229.
134. Ross, S.A., and M.A. ElSohly. 1996. The volatile oil composition of fresh and air-dried buds of Cannabis sativa. J Natl Prod 59:49-51.
135. Russo, E.B. 2000. Handbook of psychotropic herbs: A scientific analysis of herbal remedies for psychiatric conditions. Binghamton, NY: The Haworth Press, Inc.
136. Russo, E.B. 2001. Hemp for headache: an in-depth historical and scientific review of cannabis in migraine treatment. J Cann Therap 1(2):21-92.
137. 2a receptors. Poster at 41st Annual Meeting of the American Society of Pharmacognosy, July 22-26, Seattle, WA.
138. Salgueiro, J.B., P. Ardenghi, M. Dias, M.B.C. Ferreira, I. Izquierdo, and J.H. Medina. 1997. Anxiolytic natural and synthetic flavonoid ligands of the central benzodiazepine receptor have no effect on memory tasks in rats. Pharmacol Biochem Behav 58:887-891.
139. Santos, F.A., and V.S. Rao. 2000. Antiinflammatory and antinociceptive effects of 1, 8-cineole a terpenoid oxide present in many plant essential oils. Phytother Res 14(4):240-244.
140. Sauer, M.A., S.M. Rifka, R.L. Hawks, G.B. Cutler, and D.L. Loriaux. 1983. Marijuana: Interaction with the estrogen receptor. J Pharm Exper Therap 224:404-407.
141. Setzer, W.N., M.C. Setzer, D.M. Moriarity, R.B. Bates, and W.A. Haber. 1999. Biological activity of the essential oil of Myrcianthes sp. nov. "black fruit" from Monteverde, Costa Rica. Planta Med 65(5):468-469.
142. 9-tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture. Molec Pharmacol 55:8-13.
143. Shimizu, E., Y.P. Tang, C. Rampon, and J.Z. Tsien. 2000. NMDA receptor-dependent synaptic reinforcement as a crucial process for memory consolidation. Science 290:1170-1173.
144. 9-Tetrahydro-cannabinol (THC) modulates IL-1 bioactivity in human monocyte/macrophage cell lines. Life Sci 54:1281-1289.
145. Showalter, V.M., D.R. Compton, B.R. Martin, and M.E. Abood. 1996. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): Identification of cannabinoid receptor subtype selective ligands. J Pharm Exper Therap278:989-999.
146. Small, E. 1979. The species problem in cannabis. Volume 1: Science. Ottawa: Corpus Information Services Limited.
147. Sparacino, C.M., P.A. Hyldburg, and T.J. Hughes. 1990. Chemical and biological analysis of marijuana smoke condensate. NIDA Res Monogr 99:121-140.
148. Tambe, Y., H. Tsujiuchi, G. Honda, Y. Ikeshiro, and S. Tanaka. 1996. Gastric cytoprotection of the nonsteroidal anti-inflammatory sesquiterpene, beta-caryophyllene. Planta Med 62(5):469-470.
149. 9-tetrahydrocannabinol in healthy and asthmatic subjects. Am Rev Resp Dis 115:57-65.
150. Thompson, G.R., H. Rosenkrantz, U.H. Schaeppi, and M.C. Braude. 1973. Comparison of acute oral toxicity of cannabinoids in rats, dogs and monkeys. Toxicol Appl Pharmacol 25:363-373.
151. Tisserand, R., and T. Balacs. 1995. Essential oil safety: A guide for health care professionals. Edinburgh: Churchill Livingstone.
152. Turner, C.E., M.A. Elsohly, and E.G., Boeren. 1980. Constituents of Cannabis sativa L. XVII. A review of the natural constituents. J Nat Prod 43:169-304.
153. Veszki, P., G. Verzár-Petri, and S. Mészáros. 1980. Comparative phytochemical study on the cannabinoid composition of the geographical varieties of Cannabis sativa L. under the same condition. Herba Hungarica 19:95-102.
154. Vigushin, D.M., G.K. Poon, A. Boddy, J. English, G.W. Halbert, C. Pagonis, M. Jarman, and R.C. Coombes. 1998. Phase I and pharmacokinetic study of D-limonene in patients with advanced cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee. Cancer Chemother Pharmacol 42(2):111-117.
155. Walton, R.P. 1938. Marihuana, America's new drug problem. J.B. Lippincott Co., Philadelphia.
156. Wang, C., and M.S. Kurzer. 1998. Effects of phytoestrogens on DNA synthesis in MCF-7 cells in the presence of estradiol or growth factors. Nutr Cancer 31: 90-100.
157. Wilt, T.J., A. Ishani, G. Stark, R. MacDonald, J. Lau, and C. Mulrow. 1998. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. J Amer Med Assoc 280(18):1604-1609.
158. Wirth, P.W., E.S. Watson, M. ElSohly, C.E. Turner, and J.C. Murphy. 1980. Anti-inflammatory properties of cannabichromene. Life Sci 26:1991-1995.
159. Zuardi, A.W., S.L. Morais, F.S. Guimarães, and R. Mechoulam. 1995. Antipsychotic effect of cannabidiol. J Clin Psychiatr 56:485-486.
160. 9-THC in normal subjects. Psychopharmacol 76:245-250.
161. Berman, J.S., C. Symonds, and R. Birch. 2004. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain 112 (3):299-306.
162. Brady, C.M., R. DasGupta, C. Dalton, O.J. Wiseman, K.J. Berkley, and C.J. Fowler. 2004. An open-label pilot study of cannabis based extracts for bladder dysfunction in advanced multiple sclerosis. Multiple Sclerosis 10:425-433.
163. Carroll, C.B., P.G. Bain, L. Teare, X. Liu, C. Joint, C. Wroath, S.G. Parkin, P. Fox, D. Wright, J. Hobart, and J. P. Zajicek. 2004. Cannabis for dyskinesia in Parkinson disease: A randomized double-blind crossover study. Neurology 63 (7): 1245-1250.
164. de Meijer, E. 2004. The breeding of cannabis cultivars for pharmaceutical end uses. In G.W. Guy, B.A. Whittle and P. Robson (eds.), Medicinal uses of cannabis and cannabinoids (pp. 55-70). London: Pharmaceutical Press.
165. de Meijer, E.P., M. Bagatta, A. Carboni, P. Crucitti, V.M. Moliterni, P. Ranalli, and G. Mandolino. 2003. The inheritance of chemical phenotype in Cannabis sativa L. Genetics 163(1):335-346.
166. Fox, P., P. G. Bain, S. Glickman, C. Carroll, and J. Zajicek. 2004. The effect of cannabis on tremor in patients with multiple sclerosis. Neurology 62 (7):1105-1109.
167. Hillig, K.W. 2004. A chemotaxonomic analysis of terpenoid variation in Cannabis. Biochemical Systematics and Ecology 32:875-891.
168. Hillig, K.W. 2005. Genetic evidence for speciation in Cannabis (Cannabaceae). Genetic Resources and Crop Evolution 53:161-180.
169. Hillig, K.W., and P.G. Mahlberg. 2004. A chemotaxonomic analysis of cannabinoid variation in Cannabis (Cannabaceae). American Journal of Botany 91(6):966-975.
170. Mechoulam, R., L.A. Parker, and R. Gallily. 2002. Cannabidiol: An overview of some pharmacological aspects. J Clin Pharmacol 42(11 Suppl):11S-19S.
171. Nicholson, A.N., C. Turner, B.M. Stone, and P.J. Robson. 2004. Effect of delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. J Clin Psychopharmacol 24(3):305-313.
172. Notcutt, W., M. Price, R. Miller, S. Newport, C. Phillips, S. Simmonds, and C. Sansom. 2004. Initial experiences with medicinal extracts of cannabis for chronic pain: Results from 34 "N of 1" studies. Anaesthesia 59:440-452.
173. Parker, L.A., R. Mechoulam, and C. Schlievert. 2002. Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats. Neuroreport 13 (5):567-570.
174. Pertwee, R.G. 2004. The pharmacology and therapeutic potential of cannabidiol. In V. DiMarzo (ed.), Cannabinoids (pp. 32-83). Dordrecht, Netherlands: Kluwer Academic Publishers.
175. Pertwee, R.G., L.A. Stevenson, R.A. Ross, M.R. Price, K.N. Wease, and A. Thomas. 2004. The phytocannabinoid, THCV, potently antagonizes WIN55212-2 and anandamide in the mouse isolated vas deferens. In Proceedings of the British Pharmacology Society 21(4): Abstract 1P. British Pharmacology Society.
176. Russo, E.B., and G.W. Guy. 2006. A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Medical Hypotheses 60(2):234-246.
177. Teare, L.J., J.P. Zajicek, D. Wright, and L.J. Priston. 2005. What is the relationship between serum levels of cannabinoids and clinical effects in patients with multiple sclerosis and does it explain the differences between Δ9-tetrahydrocan-nabinol and whole extract of cannabis? Paper read at Conference on the cannabinoids, June 26, Clearwater, FL.
178. Varvel, S.A., D.T. Bridgen, Q. Tao, B. Thomas, B. Martin, and A. Lichtman. 2005. (Delta)9-Tetrahydrocannabinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice. J Pharmacol Exp Ther 314(1):329-337.
179. Wachtel, S.R., M.A. ElSohly, R.A. Ross, J. Ambre, and H. de Wit. 2002. Comparison of the subjective effects of delta9-tetrahydrocannabinol and marijuana in humans. Psychopharmacology 161:331-339.
180. Wade, D.T., P. Makela, H. House, C. Bateman, and P.J. Robson. 2006. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Multiple Sclerosis (in press).
181. Wade, D.T., P. Makela, P. Robson, H. House, and C. Bateman. 2004. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 10 (4):434-441.
182. Wade, D.T., P. Robson, H. House, P. Makela, and J. Aram. 2003. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clinical Rehabilitation 17:18-26.
183. Zajicek, J., P. Fox, H. Sanders, D. Wright, J. Vickery, A. Nunn, and A. Thompson. 2003. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomised placebo-controlled trial. Lancet 362(9395):1517-1526.
184. Zajicek, J., P. Fox, H. Sanders, D. Wright, J. Vickery, A. Nunn, and A. Thompson. 2004. The cannabinoids in MS study-Final results from 12 months follow-up. Mult Scler 10(suppl.):S115.